Table 1.
Genes differentially regulated with SUFU locus deletions.
| Log2 Fold Change | Av. Exp | P | P Adj | Chr | Name | Description |
|---|---|---|---|---|---|---|
| 3.66 | 1.95 | 2.23E−05 | 3.09E−02 | 1 | PTCH2 | Patched 2 tumour suppressor, indicative of aberrant Hedgehog signalling |
| 2.82 | 3.91 | 4.61E−05 | 3.64E−02 | 13 | GJB2 | Gap junction protein beta 2 |
| 2.78 | 3.53 | 1.15E−04 | 4.36E−02 | 12 | NXPH4 | Neurexophilin 4 |
| 2.35 | 1.35 | 1.18E−04 | 4.37E−02 | X | NHS | Regulates actin remodelling and cell morphology |
| 2.32 | 1.77 | 1.12E−04 | 4.32E−02 | 7 | HOXA7 | Transcription factor regulating morphogenesis and differentiation |
| 1.26 | 3.26 | 1.20E−04 | 4.38E−02 | 8 | TRPS1 | Transcriptional repressor GATA binding 1 |
| 1.09 | 2.94 | 4.48E−05 | 3.64E−02 | 1 | C1orf112 | Chromosome 1 open reading frame 112 |
| − 1.06 | 4.79 | 7.90E−06 | 2.85E−02 | 10 | ZFYVE27 | Zinc finger protein |
| − 1.11 | 5.89 | 1.18E−04 | 4.37E−02 | 16 | IL4R | Interleukin 4 receptor |
| − 1.11 | 5.30 | 4.78E−05 | 3.64E−02 | 10 | ERLIN1 | Binds cholesterol and regulates SREBP signalling pathway |
| − 1.15 | 4.37 | 1.51E−05 | 2.85E−02 | 10 | FBXL15 | F-box and leucine rich repeat protein 15 |
| − 1.18 | 7.24 | 7.23E−05 | 3.95E−02 | 10 | WBP1L | WW domain binding protein 1-like |
| − 1.33 | 4.54 | 3.28E−05 | 3.43E−02 | 10 | SUFU | Negative regulator of hedgehog signalling |
| − 1.49 | 6.14 | 1.72E−05 | 2.85E−02 | 6 | CCND3 | Regulatory subunit of CDK4 or CDK6, involved in phosphorylation Rb1 |
| − 1.51 | 6.19 | 1.10E−05 | 2.85E−02 | 3 | DTX3L | Deltex E3 ubiquitin ligase |
| − 1.52 | 5.09 | 6.97E−05 | 3.95E−02 | 22 | ODF3B | Differentially regulated in pathogenic CD4(+) T cells in MS |
| − 1.55 | 7.58 | 1.05E−04 | 4.20E−02 | 10 | MYOF | May be involved in membrane regeneration and repair |
| − 1.58 | 4.43 | 6.91E−06 | 2.85E−02 | 18 | EPB41L3 | Erythrocyte membrane protein like |
| − 1.63 | 2.83 | 9.32E−05 | 4.11E−02 | 17 | SCIMP | TLR adaptor promotes cytokine production from macrophages; involved in MHC class II signalling |
| − 2.13 | 4.41 | 9.12E−06 | 2.85E-02 | 10 | AVPI1 | Arginine vasopressin induced 1 |
| − 2.19 | 5.23 | 2.04E−05 | 3.09E−02 | 20 | SIGLEC1 | CD169: CD169 macrophages dominate antitumor immunity by presenting dead cell antigens |
| − 2.24 | 5.86 | 7.82E−05 | 3.95E−02 | 10 | IFIT3 | IFN-independent upregulation of IFN-stimulated Genes during CMV infection |
| − 2.27 | 5.68 | 3.33E−05 | 3.43E−02 | 12 | OAS2 | Involved in the innate immune response to viral infection |
| − 2.67 | 3.10 | 1.09E−04 | 4.26E−02 | 17 | CLEC10A | Specific Marker for human CD1c + dendritic cells: enhances TLR7/8-induced cytokine secretion |
| − 2.73 | 1.58 | 1.39E−04 | 4.86E−02 | 12 | KLRD1 | CD4: Killer cell receptor, may be involved in the regulation of NK cell function |
| − 2.97 | 1.89 | 1.76E−05 | 2.85E−02 | 1 | CR1 | Complement C3b/C4b receptor 1: found on dendritic and other cells |
| − 3.08 | 2.61 | 4.28E−05 | 3.64E−02 | 19 | HSH2D | Target of T-cell activation signals: TCR antigen recognition, and co-stimulation by CD28 |
| − 3.56 | 3.19 | 1.36E−04 | 4.82E−02 | 11 | HRASLS5 | HRAS like suppressor family member 5 |